Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E11.37 EPS (ttm)6.80 Insider Own0.40% Shs Outstand1.30B Perf Week-0.01%
Market Cap100.28B Forward P/E11.99 EPS next Y6.45 Insider Trans-8.51% Shs Float1.29B Perf Month8.27%
Income8.96B PEG- EPS next Q1.56 Inst Own80.60% Short Float1.06% Perf Quarter4.98%
Sales24.69B P/S4.06 EPS this Y-22.80% Inst Trans0.01% Short Ratio1.88 Perf Half Y-4.46%
Book/sh15.75 P/B4.91 EPS next Y4.37% ROA5.30% Target Price86.00 Perf Year5.38%
Cash/sh18.52 P/C4.18 EPS next 5Y-6.25% ROE15.60% 52W Range64.27 - 89.54 Perf YTD8.00%
Dividend2.28 P/FCF12.92 EPS past 5Y36.20% ROI19.90% 52W High-13.59% Beta1.04
Dividend %2.95% Quick Ratio2.80 Sales past 5Y21.90% Gross Margin82.10% 52W Low20.38% ATR1.39
Employees10000 Current Ratio2.80 Sales Q/Q-21.80% Oper. Margin50.70% RSI (14)71.98 Volatility1.54% 1.91%
OptionableYes Debt/Eq1.41 EPS Q/Q-43.10% Profit Margin14.00% Rel Volume0.77 Prev Close77.05
ShortableYes LT Debt/Eq1.29 EarningsJul 25 AMC Payout80.30% Avg Volume7.29M Price77.37
Recom2.10 SMA204.74% SMA509.13% SMA2002.80% Volume5,804,302 Change0.42%
Jun-28-18Initiated Raymond James Strong Buy
May-02-18Reiterated Maxim Group Buy $94 → $89
Mar-06-18Reiterated Barclays Overweight $90 → $95
Feb-22-18Reiterated Leerink Partners Mkt Perform $83 → $80
Feb-12-18Reiterated Mizuho Buy $83 → $95
Feb-08-18Reiterated Citigroup Buy $103 → $105
Jan-26-18Upgrade Jefferies Hold → Buy
Jan-16-18Upgrade Wells Fargo Market Perform → Outperform
Dec-20-17Downgrade Credit Suisse Outperform → Neutral
Nov-30-17Upgrade Maxim Group Hold → Buy $94
Nov-13-17Downgrade Argus Buy → Hold
Nov-08-17Reiterated Mizuho Buy $77 → $83
Oct-11-17Resumed Barclays Overweight $90
Oct-05-17Initiated Oppenheimer Perform
Oct-04-17Resumed Jefferies Hold $93
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jul-22-18 10:46AM  3 Key Things to Watch in Gilead Sciences' Q2 Earnings Report Motley Fool
Jul-20-18 02:25PM  Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings? Zacks
06:15AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-19-18 08:53AM  Gilead's Kite will partner with privately-held Gadeta to develop new cancer therapies MarketWatch
08:30AM  Kite and Gadeta Announce Strategic Collaboration to Advance Gamma Delta T Cell Receptor Technology for Solid Tumors Business Wire
Jul-17-18 06:45PM  Cramer's charts suggest big-name biotech stocks Gilead and Celgene have more room to run CNBC
09:25AM  Sure, these corporate workforces make the big bucks, but do they deserve it? American City Business Journals
Jul-16-18 08:02AM  4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit? Motley Fool
Jul-15-18 06:32AM  3 Best Big Pharma Stocks to Buy for the 2nd Half of 2018 Motley Fool
Jul-14-18 07:16AM  3 Biotech Stocks With Big News Coming in NASH Motley Fool
Jul-13-18 04:01PM  Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018 Business Wire
02:00PM  Gilead's Hot Stock May Have Further to Rise Investopedia
Jul-12-18 10:11AM  3 Real Risks That Could Make You Reconsider Buying Celgene Stock InvestorPlace
06:30AM  If You're Thinking About Buying Gilead Sciences Stock, Now's the Time to Do It Motley Fool
Jul-11-18 07:05PM  Top 5 Biotech Stocks for 2018 Investopedia
07:06AM  3 Stocks With Bullish Setups For The Rest Of The Week Benzinga
Jul-10-18 02:38PM  Nasdaq turns negative as tech stocks give up earlier gains Yahoo Finance Video
09:41AM  The Zacks Analyst Blog Highlights: Mastercard, Gilead, Goldman Sachs, PepsiCo and Aetna Zacks
09:22AM  Trade of the Day: Gilead Sciences (GILD) InvestorPlace
Jul-09-18 05:39PM  Portfolio manager Stephanie Link's two new stock picks CNBC Videos
04:30PM  Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy Business Wire
11:42AM  Top Research Reports for Mastercard, Gilead & Goldman Sachs Zacks
06:00AM  4 Biotechs on Verge of Big Breakouts Investopedia
Jul-06-18 05:29PM  Is health care the ultimate hideout trade? CNBC Videos
04:56PM  Health care stocks have even more room to run, technician... CNBC Videos
03:13PM  Why Biotech Stocks Rallied on Biogen's Alzheimer's Test Zacks
12:48PM  7 Stocks That Can Lead The Market Longterm Investopedia
12:26PM  Biotech Stocks Rally on Biogen's Landmark Test TheStreet.com
10:30AM  Gilead Sciences Is Displaying a Bullish Long-Term Pattern TheStreet.com
08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
Jul-05-18 06:17PM  Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More Zacks
02:40PM  Drug pricing debate could heat up in July CNBC Videos
10:30AM  Gilead: A Top Biotech Pick for a Turnaround Barrons.com
Jul-03-18 09:35AM  Is Gilead Sciences a Great Stock for Value Investors? Zacks
Jul-02-18 08:55AM  Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion Zacks
Jun-29-18 12:44PM  UPDATE 1-Rival Novartis, Gilead CAR-T therapies win European panel recommendation Reuters
08:16AM  Rival Novartis, Gilead CAR-T therapies win European panel recommendation Reuters
07:54AM  European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy Business Wire
Jun-28-18 02:42PM  Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock Benzinga
Jun-27-18 08:12AM  Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod Zacks
Jun-26-18 08:39AM  Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection Zacks
07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-25-18 08:03AM  European Commission Grants Marketing Authorization for Gileads Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection Business Wire
Jun-22-18 07:07PM  Cramer's lightning round: I don't like Snap's ownership s... CNBC Videos
06:47PM  Cramer's lightning round: I don't like Snap's ownership structure CNBC
Jun-21-18 02:27PM  Gilead Sciences Inc (NASDAQ:GILD): Should The Recent Earnings Drop Worry You? Simply Wall St.
11:49AM  3 Big Biotechs That Can Beat the Market Investopedia
Jun-20-18 11:30AM  2 High-Flying Biotech Stocks With Even More Room to Grow Motley Fool
09:51AM  Glaxo Venture's Lofty Goal in HIV: Eclipse Gilead as Top Player Bloomberg
08:59AM  GSK takes billion-dollar drug fight with Gilead to top AIDS meeting Reuters
Jun-19-18 06:32AM  3 Great Reasons to Buy Gilead Sciences Motley Fool
Jun-17-18 08:00AM  1 Under-the-Radar Dividend Growth Stock to Buy Right Now Motley Fool
Jun-15-18 02:31PM  Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers Motley Fool
10:37AM  Big Biotech Set for Earnings Blowout? Barrons.com
09:11AM  Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant Zacks
Jun-14-18 04:23PM  Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV Investor's Business Daily
09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
09:01AM  GSK's two-drug HIV treatment meets main goal in late stage studies Reuters
08:30AM  Consolidated Research: 2018 Summary Expectations for Encana, Netflix, Veon, The Walt Disney, Gilead Sciences, and Cloudera Fundamental Analysis, Key Performance Indications GlobeNewswire
07:05AM  Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE
Jun-11-18 08:30AM  Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia CNBC
08:30AM  Gilead Sciences Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia Business Wire
Jun-07-18 05:36PM  Should You Stick With Gilead Sciences? Motley Fool
10:16AM  Gilead: The Turnaround Is Happening This Year Barrons.com
06:00AM  Gilead's Hot Stock May Cool Fast Investopedia
Jun-06-18 03:34PM  Gilead Collaborates with Hookipa for HBV and HIV Therapies Zacks
08:31AM  Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO Zacks
06:02AM  2 Cheap Dividend Stocks You Can Buy Right Now Motley Fool
Jun-05-18 07:01PM  New Ebola Outbreak May Open Door to Finding Drugs Bloomberg
08:20AM  Today's Research Reports on Trending Tickers: Gilead Sciences and bluebird bio ACCESSWIRE
12:21AM  After Soaring to New Highs, Crispr Therapeutics AG Stock Ripe for a Fall InvestorPlace
Jun-04-18 05:00PM  Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy Business Wire
09:00AM  Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting Business Wire
09:00AM  Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors Business Wire
Jun-03-18 11:35AM  Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy MarketWatch
09:33AM  3 Reasons Gilead Sciences Is a Better Value Stock Than Amgen Motley Fool
Jun-01-18 04:40PM  Conquering cancer in the Windy City CNBC Videos
12:49PM  Has the Gilead Sciences Buy Argument Collapsed? Motley Fool
11:08AM  Better Know Biotech: 2 Stocks You've Got to Know About Motley Fool
07:05AM  Blog Exposure - Gilead Announces Approval of Epclusa in China ACCESSWIRE
06:15AM  5 Top Stocks to Buy in June Motley Fool
May-31-18 01:42PM  ASCO Conference Preview: Here's What Biotech Investors Need to Watch Motley Fool
11:05AM  Peaking late: How Vertex became biotech's model citizen American City Business Journals
11:00AM  Is GlaxoSmithKline plc Stock a Buy? Motley Fool
10:34AM  Gilead & Galapagos Announce Positive Data on Filgotinib Zacks
10:21AM  2018 ASCO Conference Roundup Motley Fool
09:11AM  Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report? Zacks
May-30-18 09:03PM  Read This Before You Buy Immuno-Oncology Stocks Motley Fool
04:02PM  GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS GlobeNewswire
04:01PM  Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13 Business Wire
04:01PM  Gilead and Galapagos Announce Results With Filgotinib in the Phase 2 Equator Study in Psoriatic Arthritis and Progression Into Phase 3 for the Selection Study in Ulcerative Colitis Business Wire
01:33PM  Trump says drugmakers are going to announce massive voluntary price cuts in two weeks CNBC
11:43AM  Biotech ETFs Are the Best Way to Play the Recovering Sector InvestorPlace
08:26AM  Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod Zacks
08:14AM  Benzinga's Daily Biotech Pulse: Chinese Cheer For Gilead, Immutep Presents Positive Phase 1 Data, FDA Accepts Exelixis sNDA Benzinga
01:00AM  China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gileads Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection Business Wire
May-29-18 10:16AM  3 Top Value Stocks to Buy Now Motley Fool
May-27-18 06:32AM  3 Healthcare Stocks That Are Undeniably Dirt Cheap Right Now Motley Fool
May-24-18 11:07AM  Will Right to Try Bill Boost Biotech ETFs? ETF Trends
May-23-18 04:01PM  Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 Business Wire
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen Sciences Ireland UC, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CDirectorJul 02Option Exercise23.6050,0001,180,0003,067,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJul 02Sale70.8150,0003,540,2823,017,762Jul 05 08:00 PM
MARTIN JOHN CDirectorJun 01Option Exercise23.6050,0001,180,0003,067,762Jun 05 07:34 PM
MARTIN JOHN CDirectorJun 01Sale68.1350,0003,406,4953,017,762Jun 05 07:34 PM
Cogan John FrancisDirectorMay 04Option Exercise26.625,836155,32558,455May 08 01:59 PM
MILLIGAN JOHN FPresident and CEOMay 04Option Exercise27.0780,0002,165,6001,294,306May 08 06:29 PM
Cogan John FrancisDirectorMay 04Sale65.095,836379,88552,619May 08 01:59 PM
MARTIN JOHN CDirectorMay 01Option Exercise23.6050,0001,180,0003,067,762May 03 01:07 PM
MARTIN JOHN CDirectorMay 01Sale72.1950,0003,609,6603,017,762May 03 01:07 PM
Cogan John FrancisDirectorApr 27Option Exercise26.625,833155,24558,452Apr 30 05:39 PM
Cogan John FrancisDirectorApr 27Sale73.915,833431,11752,619Apr 30 05:39 PM
Cogan John FrancisDirectorApr 20Option Exercise26.625,833155,24558,452Apr 23 07:16 PM
Cogan John FrancisDirectorApr 20Sale73.745,833430,13052,619Apr 23 07:16 PM
Cogan John FrancisDirectorApr 13Option Exercise26.625,833155,24558,452Apr 16 06:45 PM
Cogan John FrancisDirectorApr 13Sale75.565,833440,74152,619Apr 16 06:45 PM
Cogan John FrancisDirectorApr 06Option Exercise26.625,833155,24558,452Apr 09 06:41 PM
Cogan John FrancisDirectorApr 06Sale74.475,833434,38452,619Apr 09 06:41 PM
Cogan John FrancisDirectorApr 02Option Exercise26.625,833155,24558,452Apr 04 04:23 PM
MARTIN JOHN CDirectorApr 02Option Exercise23.6050,0001,180,0003,067,762Apr 04 07:34 PM
MARTIN JOHN CDirectorApr 02Sale73.1450,0003,656,8063,017,762Apr 04 07:34 PM
Cogan John FrancisDirectorApr 02Sale74.935,833437,06752,619Apr 04 04:23 PM
Cogan John FrancisDirectorMar 23Option Exercise26.625,833155,24558,452Mar 26 06:48 PM
Cogan John FrancisDirectorMar 23Sale75.025,833437,58852,619Mar 26 06:48 PM
Cogan John FrancisDirectorMar 16Option Exercise26.625,833155,24558,452Mar 20 01:28 PM
Cogan John FrancisDirectorMar 16Sale80.095,833467,13852,619Mar 20 01:28 PM
Cogan John FrancisDirectorMar 12Option Exercise26.625,833155,24558,452Mar 13 04:29 PM
Cogan John FrancisDirectorMar 12Sale80.935,833472,06552,619Mar 13 04:29 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise23.6050,0001,180,0003,067,762Mar 05 06:54 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Option Exercise40.5617,250699,66069,426Mar 05 07:04 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00178012,233Mar 05 08:42 PM
Alton Gregg HEVP,Corporate &Medical AffairsMar 01Sale78.6925,0001,967,31544,426Mar 05 07:04 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale78.6550,0003,932,3753,017,762Mar 05 06:54 PM
Washington Robin LEVP, CFOFeb 28Sale80.315,000401,566105,405Mar 02 06:47 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 20Sale81.5414,4351,176,9920Feb 21 06:51 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.00908016,237Feb 13 04:58 PM
WILSON GAYLE EDirectorFeb 09Option Exercise26.6260,0001,596,900182,258Feb 13 05:24 PM
WILSON GAYLE EDirectorFeb 09Sale77.9260,0004,675,080122,258Feb 13 05:24 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise23.6050,0001,180,0003,046,766Feb 05 08:38 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Option Exercise40.5617,250699,66062,738Feb 05 09:20 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.00620015,547Feb 02 09:14 PM
Alton Gregg HEVP,Corporate &Medical AffairsFeb 01Sale83.5125,0002,087,86037,738Feb 05 09:20 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale83.5650,0004,177,8242,996,766Feb 05 08:38 PM
Meyers James REVP Worldwide Commercial OpsJan 16Option Exercise21.58100,0002,157,500102,715Jan 18 06:31 PM
Meyers James REVP Worldwide Commercial OpsJan 16Sale80.24100,0008,024,3642,715Jan 18 06:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Option Exercise36.0225,875932,06275,488Jan 16 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 11Sale79.0030,0002,370,00045,488Jan 16 05:42 PM
MARTIN JOHN CExecutive ChairmanJan 02Option Exercise23.6050,0001,180,0003,046,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Option Exercise24.918,625214,80664,613Jan 04 08:05 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJan 02Sale73.8715,0001,108,01949,613Jan 04 08:05 PM
MARTIN JOHN CExecutive ChairmanJan 02Sale73.6250,0003,681,2352,996,766Jan 04 07:54 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Option Exercise24.918,625214,80670,988Dec 05 06:17 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise21.5873,3331,582,1593,070,099Dec 05 07:49 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale74.9873,3335,498,3852,996,766Dec 05 07:49 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffDec 01Sale74.6415,0001,119,55255,988Dec 05 06:17 PM
MILLIGAN JOHN FPresident and CEONov 13Option Exercise21.58220,0004,746,5001,385,924Nov 15 03:19 PM
MILLIGAN JOHN FPresident and CEONov 13Sale72.88220,00016,034,6781,165,924Nov 15 03:19 PM
Meyers James REVP Worldwide Commercial OpsNov 05Option Exercise0.004,50007,215Nov 07 05:47 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Option Exercise24.918,625214,80677,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise21.5873,3331,582,1593,070,099Nov 03 07:04 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale75.1373,3335,509,6972,996,766Nov 03 07:04 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 01Sale74.8215,0001,122,28562,363Nov 03 06:59 PM
MARTIN JOHN CExecutive ChairmanOct 02Option Exercise21.5873,3331,582,1593,070,099Oct 04 07:19 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Option Exercise24.9117,250429,61193,738Oct 04 07:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffOct 02Sale82.6525,0002,066,30768,738Oct 04 07:26 PM
MARTIN JOHN CExecutive ChairmanOct 02Sale82.5673,3336,054,3192,996,766Oct 04 07:19 PM
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM